摘要
目的观察肥胖2型糖尿病患者采用不同药物治疗的临床价值及安全性。方法将该院2012年10月—2015年10月收治的65例肥胖2型糖尿病患者分为胰岛素治疗的对照组及加用利拉鲁肽治疗的观察组,对两组患者的血糖指标、血脂指标的变化情况,低血糖及其他不良反应发生率进行观察和统计。结果观察组患者治疗后血糖、血脂指标的改善效果明显优于对照组(P<0.05);观察组患者低血糖发生率及不良反应发生率明显低于对照组(P<0.05)。结论肥胖2型糖尿病患者采用胰岛素治疗期间加用利拉鲁肽联合治疗的临床效果显著,有效改善了患者的血糖、血脂水平,值得推广。
Objective To observe the clinical value and safety of different drug therapy in obese patients with type 2 dia-betes. Methods 55 obese patients with type 2 diabetes admitted in our hospital from October 2012 to October 2015 were divided into insulin control group and observation group treated with liraglutide. The blood glucose level , Blood lipid changes, low blood sugar and other adverse reaction rates were observed and statistics. Results The improvement of blood glucose and blood lipid in the observation group was better than that in the control group （P 〈0.05）. The incidence of hypoglycemia and the incidence of adverse reactions were significantly lower in the observation group than in the control group （P 〈0.05）. Conclusion The clinical effect of combination therapy of insulin and lilaluzide during obese type 2 diabetes pa-tients was significantly improved, and the level of blood glucose and blood lipid of patients with type 2 diabetes mellitus was improved.
作者
张亚娜
ZHANG Ya-na(Shuangyashan Double Ore Hospital Pharmacy Department, Shuangyashan,Heilongjiang Province, 155100 China)
出处
《糖尿病新世界》
2017年第3期63-64,共2页
Diabetes New World Magazine
